Fader AN, et al. - Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. Patients who received carboplatin-paclitaxel with and without trastuzumab for advanced or recurrent uterine serous carcinoma with overexpression of HER2/neu were examined for progression-free survival. Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival.